Quantum Biopharma Class B Subordinate Voting Shares
QNTM
24 hedge funds and large institutions have $937K invested in Quantum Biopharma Class B Subordinate Voting Shares in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
41% more funds holding
Funds holding: 17 → 24 (+7)
1.59% more ownership
Funds ownership: 1.78% → 3.36% (+1.6%)
5% more capital invested
Capital invested by funds: $895K → $937K (+$41.3K)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$173K |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$135K |
| 3 |
GS
GTS Securities
New York
|
+$134K |
| 4 |
Jane Street
New York
|
+$119K |
| 5 |
VF
Virtu Financial
New York
|
+$114K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$76.8K |
| 2 |
Morgan Stanley
New York
|
-$25.3K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$5.76K |
| 4 |
JP Morgan Chase
New York
|
-$1.74K |
| 5 |
SS
SBI Securities
Tokyo,
Japan
|
-$1.09K |
QNTM Hedge Fund Activity: Q4 2025 in Review
24 of the 8,238 institutional investors tracked by Wall St. Rank reported a position in Quantum Biopharma Class B Subordinate Voting Shares (QNTM) for Q4 2025, worth a combined $937K — up 4.6% from $895K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new QNTM positions and 2 closed out — a net gain of 7 holders — while 4 added to existing stakes and 6 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $173K. The largest seller was UBS Group, cutting an estimated $76.8K.
- 24 institutional investors held Quantum Biopharma Class B Subordinate Voting Shares (QNTM) as of Q4 2025, up from 17 in Q3 2025.
- Funds reported $937K of Quantum Biopharma Class B Subordinate Voting Shares stock for Q4 2025, up 4.6% quarter-over-quarter.
- 9 funds opened new Quantum Biopharma Class B Subordinate Voting Shares positions in Q4 2025 and 2 closed out, a net change of +7 holders.
- The largest Quantum Biopharma Class B Subordinate Voting Shares buyer in Q4 2025 was Citadel Advisors, an estimated $173K added.
- The largest Quantum Biopharma Class B Subordinate Voting Shares seller in Q4 2025 was UBS Group, an estimated $76.8K sold.
Based on aggregated 13F filings for Q4 2025.